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ABSTRACT:
Proliferating cancer cells oxidize glucose through the glycolytic pathway. Since 
this metabolism is less profitable in terms of ATP production, cancer cells consume 
large quantity of glucose, and those that experience insufficient blood supply become 
glucose-addicted. We have analyzed the response to glucose depletion in WRO and 
FTC133 follicular thyroid cancer cells, which differ in the expression of two key 
regulators of the glucose metabolism. WRO cells, which express wild type p53 and 
PTEN, showed a higher rate of cell proliferation and were much less sensitive to 
glucose-depletion than FTC133 cells, which are PTEN null and express mutant p53. 
Glucose depletion slowed-down the autophagy flux in FTC133 cells, not in WRO cells. 
In a wound-healing assay, WRO cells were shown to migrate faster than FTC133 
cells. Glucose depletion slowed down the cell migration rate, and these effects were 
more evident in FTC133 cells. Genetic silencing of either wild-type PTEN or p53 in 
WRO cells resulted in increased uptake of glucose, whereas the ectopic expression of 
PTEN in FTC133 cells resulted in diminished glucose uptake. In conclusion, compared 
to WRO, FTC133 cells were higher glucose up-taker and consumer. These data do 
not support the general contention that cancer cells lacking PTEN or expressing the 
mutant p53R273H are more aggressive and prone to better face glucose depletion. 
We propose that concurrent PTEN deficiency and mutant p53 leads to a glucose-
addiction state that renders the cancer cell more sensitive to glucose restriction. 
The present observation substantiates the view that glucose-restriction may be an 
adjuvant strategy to combat these tumours.
INTRODUCTION
Glucose is an essential precursor for the synthesis 
of various macromolecules and the main source of the 
energy needed in the survival and biosynthetic pathways. 
Normally, in the presence of oxygen, glucose is oxidized 
through the mitochondrial respiration pathway with the 
highest rate of production of ATP. However, in highly 
proliferating cancer cells glucose is preferentially 
converted into lactate despite the presence of oxygen 
and functional mitochondria. This aberrant metabolism 
of glucose, known as the Warburg effect or aerobic 
glycolysis, is much less convenient in terms of energy 
gain, and imposes a large consumption of glucose in 
proliferating cells[1,2]. Vascularization is defective 
and insufficient in fast growing solid tumours and, 
consequently, the cells located distant from the blood 
vessels experience a lack of glucose and oxygen[3]. Under 
these conditions, cancer cells activate autophagy, a pro-
survival lysosomal degradation pathway, and produce 
Genes & Cancer227www.impactjournals.com/Genes & Cancer
large quantity of lactic acid. Autophagy itself promotes the 
metabolic switch toward glycolysis, thus facilitating cell 
survival and cell proliferation[4]. In addition, autophagy 
and glycolysis are also involved in the ‘epithelial-to-
mesenchymal’ transition phenomenon that precedes the 
metastasization[5-7]. Therefore, glucose availability 
and modulation of autophagy have a great impact on the 
malignant behaviour of cancer cells. 
PTEN and TP53 are the most common deleted or 
mutated oncosuppressors found in human carcinomas. 
These two oncosuppressors are key regulators of the 
glucose metabolism and of autophagy[8-11]. Either PTEN 
deficiency or p53 mutation has been shown to confer the 
ability to cancer cells to overcome the metabolic stress 
caused by hypoxia and nutrients (including glucose) 
depletion, and to be the driving force for cell proliferation 
and cell migration[8,9,12,13]. Here, we have tested 
whether combined PTEN deficiency and p53 mutation 
indeed confers a metabolic advantage to cancer cells in 
response to glucose depletion in terms of cell survival, 
cell proliferation and cell migration, and of autophagy 
response. As a cell model, we employed the follicular type 
thyroid cancer cell lines WRO and FTC-133. WRO cells 
express wild-type PTEN and p53, whereas FTC133 cells 
are PTEN-deficient and express the anti-apoptotic and 
anti-autophagic p53R273H mutant[14,15]. We found that 
FTC133 cells were more active up-taker and consumer 
of glucose than WRO cells. Consistently, the facilitative 
glucose transporter GLUT1 was basally expressed at 
higher level on the plasmamembrane of FTC133 cells than 
on that of WRO cells. Through genetic manipulations we 
could demonstrate that both the membrane translocation 
of GLUT1 and the uptake of glucose are controlled 
by PTEN and p53. Unexpectedly, FTC133 cells were 
revealed to be more sensitive to glucose-depletion in terms 
of cell growth, survival and migration, and of autophagy 
completion, than WRO cells. The present data indicate 
that the synergistic effects of combined PTEN deficiency 
and p53 mutation render the cancer cells glucose-addicted 
and therefore more sensitive to glucose deprivation. 
RESULTS
Effect of glucose depletion on PTEN and p53 in 
WRO and FTC133 cells
The effect of glucose depletion on PTEN and p53 
expression was analyzed in WRO and FTC133 thyroid 
cancer cells. To this end, the cells were cultivated in 
glucose-containing (2 g/L for RPMI and 4.5 g/L for 
DMEM, respectively for WRO and FTC133 cells) or in 
glucose-free standard medium for 24 h and then analyzed 
by western blotting. Both these cell types present no 
mutations in the RAS and PI3kCA genes, while FTC133 
cells present the following unique mutations: the R273H 
P53 mutation and the R130STOP PTEN mutation[14]. 
FTC133 cells have also been reported to bear a 
monoallelic deletion of PTEN[15].
As a consequence of the mutations, PTEN protein 
was not detectable in FTC133 cells (Figure 1A). In WRO 
cells, PTEN was expressed at high level and its expression 
was not subjected to substantial changes in dependence 
of glucose availability (Figure 1A). The mutant p53 
was highly expressed in FTC133 cells, when compared 
to the expression of the wild-type p53 in WRO cells 
(Figure 1B). This finding is consistent with literature 
data on the abnormal hyper-expression of mutant p53 in 
tumours. Noteworthy, glucose depletion greatly reduced 
the protein level of the mutant p53 in FTC133 cells, 
not that of the wild-type p53 in WRO cells (Figure 1B).
Figure 1: The effect of glucose availability on the 
expression of PTEN and p53 in WRO and in FTC133 
cells. WRO and FTC133 cells were plated and let adhere on 
Petri dishes and then incubated for 24 h in glucose-rich or 
in glucose-free standard medium. Cell homogenates were 
analyzed by western blotting for the expression of PTEN, ser15-
phosphorylated p53 and total p53 as indicated, respectively 
in panel A and B. The filters were stripped and re-probed for 
β-tubulin as a protein loading marker. Densitometry of p53 bands 
in panel B is included. The blots here shown are representative 
of n=3 independent experiments. Glucose-dependent difference 
in the expression of PTEN in WRO cells (panel A) was not 
statistically significant. 
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Phosphorylation of p53 at ser15 stabilizes the protein and 
is indicative of its activation. In fact, wild-type p53 was 
phosphorylated and its protein level slightly increased in 
WRO cells cultivated for 24 h in glucose-free medium. 
Unexpectedly, a large proportion of the mutant p53 in 
FTC133 cells was phosphorylated, and about one-third of 
it was degraded upon 24 h glucose depletion (Figure 1B). 
These data indicate that WRO and FTC133 cells respond 
differently to glucose depletion in terms of p53 activation 
and stability. 
Glucose depletion differentially affects WRO and 
FTC133 cell proliferation
To determine the effect of glucose depletion on 
cell proliferation, WRO and FTC133 cells were plated at 
the same starting density, let adhere for 24 h in glucose-
containing complete medium (cell density at this time was 
considered as t0), then washed and further cultivated in 
glucose-containing or glucose-free medium for up to 48 h 
without medium change. Cell density was evaluated at 24 
h and 48 h of incubation and the doubling time (Dt) of the 
cell population was calculated (Table 1). In the presence of 
glucose, the rate of proliferation (as mirrored by the Dt) in 
both cell types remained substantially unaltered, indicating 
that the consumption of nutrients (glucose, aminoacids) in 
the first 24 h did not affect much the duplication potential 
in the subsequent 24 h of incubation. Strikingly, the Dt 
of FTC133 cells was two folds longer than that of WRO 
cells, and this in spite of the fact that they were cultured 
in high-glucose medium. When incubated in the absence 
of glucose, the Dt increased for both cell types, indicating 
a strict dependence on the availability of glucose for their 
duplication. However, in WRO the Dt only increased by 
1.5-folds (from ~13.5 h to ~22.5 h) while in FTC133 the 
Dt increased by 3.5-fold (from 27 h to 96 h), i.e. more than 
two times. The different dependency from glucose for cell 
duplication became even more evident when evaluated 
after 48 h of culture in glucose-free medium. Under this 
condition, the Dt of FTC133 cells was approximately four-
times that of WRO cells (230 h vs 60 h). 
The difference in the response to glucose availability 
between the two cell lines was further substantiated by 
the cell cycle analysis (Figure 2). Between 24 h and 48 h, 
Figure 2: Different growth response to glucose 
availability between WRO and FTC133 cells. WRO 
and FTC133 cells were let adhere for 24 h in complete medium 
and then cultivated in glucose-containing or in glucose-free 
standard medium for up to 48 h without medium change. At 
the end, adherent and suspended cells were recovered, fixed in 
ethanol and labelled with propidium iodide (PI). Finally, the 
cells were analyzed by cytofluorometry to determine the phases 
of cell cycle. In panels A-H are shown the percentages of the 
four cell cycle phases (Sub G1, G0/G1, S, G2/M) obtained 
using the software Win MDI 2.9. During glucose depletion 
WRO cells accumulated in the G0/G1 retarding the entry in the 
S phase (panels C-D vs A-B) and only a small fraction of the 
cells underwent apoptosis (panel D); FTC133 cells in the first 
24 h accumulated in G2/M and underwent apoptosis (indicated 
by subG1 peak, panels G), while in the following 24 h decreased 
the fraction of cells in G2/M and increased the fraction of subG1 
population (panel H vs G). Data shown in this Figure have been 
reproduced independently four times. 
Table 1: Doubling time of WRO and FTC133 cells after 
incubation in glucose-containing complete medium or 
in glucose-free medium.
24h 48h
WRO +glucose 13.47 ± 1.46 16.33 ± 2.54
WRO -glucose 22.43 ± 3.83 60.09 ± 5.91
FTC133 +glucose 27.08 ± 4.89 26.4 ± 5.05
FTC133 –glucose 95.9 ± 4.47 228.83 ± 0.74
In the presence of glucose the doubling time of FTC133 cells 
was two-folds longer than that of WRO cells. In glucose 
depleted culture condition, the doubling time of FTC133 cells 
increased much more than that of WRO cells, indicating a higher 
dependence on the availability of glucose for their duplication.
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WRO cells cultivated in the presence of glucose slightly 
increased the fraction in G0/G1, while not changing the 
amount in the S phase (panel B vs A). These data are in 
agreement with the substantial similar Dt calculated at 24 
and 48 h (see Table 1). When cultivated in the absence 
of glucose, WRO reduced the fraction in the S phase and 
tended to accumulate in the G0/G1, indicating that the lack 
of glucose retarded the entry in the S phase (panel C vs A). 
In the following 24 h of culture without glucose (panel D 
vs C) no changes were observed, besides the fact that a 
small fraction (4%) of the WRO cells resting in G0/G1 
underwent apoptosis (as indicated by the apparent increase 
of the subG1 peak). 
Between 24 h and 48 h in glucose-containing 
medium, FTC133 cells reduced their fraction in S and 
G2/M phases to accumulate in the G0/G1 phase, likely as 
a consequence of the consumption of nutrients in the first 
24 h, but no increase of the SubG1 fraction was recorded 
(panel F vs E). When cultivated for 24 h in the absence of 
glucose, FTC133 cells reduced their fraction in the G0/
G1 and S phases, and tended to accumulate in the G2/M 
phase and also to undergo apoptosis (as indicated by the 
increase in the subG1 peak), suggesting that the lack of 
glucose could have impaired the completion of the mitotic 
process (panel G vs E). In the following 24 h of culture 
without glucose the above effect was even more evident, 
as the fraction of FTC133 cells in G2/M further decreased 
and correspondingly increased the fraction in the subG1 
population (panel H vs G). 
Overall, these data demonstrate that FTC133 are 
much more sensitive than WRO cells to nutrient shortage, 
especially to glucose starvation.
Figure 3: Glucose depletion induces apoptotic cell death in FTC133 cells. A) WRO and FTC133 cells were cultivated in 
glucose-containing or in glucose-free standard medium for up to 48 h without medium change in the absence or presence of the pan-
caspase inhibitor z-VAD-fmk, and then counted. In glucose depletion condition, no apoptosis occurred in WRO cells, while in FTC133 
cells apoptotic cell death occurred at 24 h (partially rescued by z-VAD-fmk). B) Cytofluorometry analysis of the cell cycle in FTC133 
cells cultivated in glucose-free condition for up to 48 h in the absence or presence of the pan-caspase inhibitor z-VAD-fmk confirmed the 
induction of apoptotic cell death at 24 h. Z-VAD-fmk prevented apoptosis in the first 24 h and arrested the cell cycle in the G2/M phase, 
avoiding necrosis, in the following 24 h (48 h). Data shown in this Figure have been reproduced independently four times. 
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Glucose depletion differentially affects WRO and 
FTC133 cell survival 
To assess whether glucose depletion caused 
apoptosis to FTC133 cells, we repeated the experiment 
in the presence of the pan-caspases inhibitor z-VAD-fmk. 
No apoptosis occurred in WRO cells cultivated under any 
conditions, while in the case of FTC133 cells cultivated 
in the absence of glucose a portion of cell loss could be 
rescued by z-VAD-fmk at 24 h, but not at 48 h (Figure 
3A). The latter finding was in apparent contrast with the 
data shown in Figure 2H. However, a cytofluorometric 
analysis of the cell cycle confirmed that in fact z-VAD-
fmk effectively reduced the subG1 peak (indicative of 
apoptosis) while increasing the fractions in the G2/M 
phase (Figure 3B). Consistently, in the presence of z-VAD-
fmk the percentage of FTC133 cells positively stained 
with trypan blue, a dye that monitors necrosis, decreased 
from approximately 18% to 7% in the 48 h culture in 
glucose-free medium. Thus, in FTC133 cells cultivated 
for 48 h in the absence of glucose, z-VAD-fmk prevented 
apoptosis in the first 24 h, while in the subsequent 24 h it 
caused a general block of the cell cycle that prevented the 
onset of necrosis. 
Glucose availability differentially impact 
autophagy in WRO and FTC133 cells 
The autophagy-lysosomal degradation pathway 
is up-regulated under stressful metabolic conditions 
to provide the cells with anabolic substrates necessary 
for survival[16]. Nutrients (essentially aminoacids and 
glucose) shortage, as well as the lack of growth factors, 
are strong stimuli for rising up basal autophagy to the 
level needed to overcome the metabolic stress[16]. The 
altered expression of PTEN and p53 is likely to affect the 
regulation of autophagy in thyroid cancers[17]. 
It seemed therefore important to check whether 
the different susceptibility to glucose deprivation 
manifested by WRO and FTC133 cells could be associated 
Figure 4: Induction of autophagy in WRO and FTC133 cells by glucose depletion. A) Western blotting analysis of the 
autophagosome marker LC3 II in WRO and FTC133 cells cultivated for 24 h in glucose-containing or in glucose-free standard medium in 
the absence or the presence of the PI3k inhibitor 3MA (10mM). The densitometry ratio of LC3 II normalized versus β-tubulin is reported. 
3MA inhibited glucose-depletion induced autophagy more in WRO cells than in FTC133 cells. B-C) Western blotting analysis showing 
LC3 II levels in WRO cells (B) and in FTC133 cells (C) cultivated for 24 h and 48 h in glucose-containing or in glucose-free standard 
medium in the absence or the presence of the weak base ammonium chloride (NH4Cl, 10mM). The densitometry ratio of LC3 II normalized 
vs β-tubulin is reported. Under glucose depletion autophagy induction appeared similar in the first 24 h for both the cell lines, instead at 48 
h the autophagy flux was impaired in FTC133 cells. Data shown in this Figure have been reproduced independently three times.
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with an altered activation of the autophagy pawthay. 
During autophagosome formation, LC3 must be post-
translationally conjugated to phosphatydil-ethanolamine in 
order to be inserted onto the autophagosomal membranes. 
This processing increases the apparent electrophoretic 
mobility of LC3, thus making easy in western blotting 
to distinguish the precursor LC3-I (apparent m.w. of 18 
kDa) and the mature isoform LC3-II (apparent m.w. of 16 
kDa). In the canonical regulatory pathway of autophagy, 
PI3k class III (also known as Vps34) provides the essential 
starting signal for the autophagosome formation. We 
included in our incubation conditions 3-methyl adenine 
(3MA), an inhibitor of PI3k. This drug is widely employed 
as a pharmacological inhibitor of autophagy[18], though 
it has been reported that depending on the cell line and 
the dose and time of incubation it might elicit a paradoxic 
induction of autophagy[19]. Based on the assumption that 
the cellular level of LC3-II reflects the autophagosomes 
present in the cells, it appears that in standard culture 
condition autophagy is basally (2.5-folds) higher in 
FTC133 than in WRO cells (Figure 4A). 3MA inhibited 
only partially basal autophagy in FTC133 cells, not in 
WRO cells. Glucose depletion induced autophagy in both 
cell lines, yet the response was higher in WRO than in 
FTC133 cells (the increases of LC3-II in glucose-deprived 
samples were of 10-folds and of 2.2-folds above the 
controls, respectively). Of note, 3MA effectively inhibited 
glucose-deprivation induced autophagy in WRO cells, 
and only slightly in FTC133 cells. The increase of LC3-II 
per se not necessarily proves the induction of autophagy, 
since it might also simply represent the accumulation 
of autophagosomes resulting from the block of their 
consumption within the lysosomes[18]. To discriminate 
true autophagosome production from autophagosome 
accumulation, it is useful to artificially impair the fusion 
and degradation steps by using a lysosomal pH disruptor 
such as ammonium chloride[18]. In the following 
experiments, we assessed the amount of LC3-II in the cells 
incubated in the presence of ammonium chloride. Under 
standard (glucose-containing) culture condition, basal 
autophagy runs at higher level in WRO than in FTC133 
cells, as indicated by the higher accumulation of LC3 II 
in the presence of ammonium chloride (Figure 4B). At 
48 h (with no change of medium), only FTC133 cells 
have increased the production of autophagosomes. In the 
absence of glucose, autophagy is induced both in WRO 
and FTC133 cells and the production/consumption rates 
of autophagosomes (based on LC3 II accumulation in the 
absence/presence of ammonium chloride) appear similar 
in the first 24 h. However, at 48 h WRO cells do not 
produce new autophagosomes, and rather consume all the 
pre-existing ones, whereas FTC133 cells still accumulate 
a large part of the pre-existing autophagosomes 
indicating that the last step of the autophagy flux is 
impaired. The above data were further corroborated by 
immunofluorescence staining of LC3-positive vacuoles 
Figure 5: Glucose depletion differentially affect cell 
migration of WRO and FTC133 cells. WRO and FTC133 
cells were plated and let grow to confluence in Petri dishes in 
glucose-containing standard medium, then a scratch-wound 
was made using a tip and the cell cultures were switched into 
glucose-containing or glucose-free conditions and cultured for 
up to 48 h. Photographs of the wound were taken at time 0 and 
at 8, 24 and 48 h. The wound area and the percentage of healing 
were calculated for each time point. WRO cells showed a higher 
migration rate than FTC133 cells. Data shown in this Figure 
have been reproduced independently three times. 
Table 2: Percentage of healing in WRO cells (A) and in 
FTC133 cells (B) in glucose-containing or glucose-free 
condition at 8 h, 24 h, and 48 h.
A)
WRO










Migration was quantified by calculating the area of the wound at 
the different time points. Cell migration was slower in FTC133 
cells than in WRO cells, and in the absence of glucose migration 
was further reduced.
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(not shown). 
Glucose depletion differentially affect WRO and 
FTC133 cell migration 
To assay the influence of glucose availability on the 
migratory potential of thyroid cancer cells, we tested the 
effect of glucose deprivation in a classical scratch-wound 
healing assay[20]. WRO cells showed a higher migration 
rate than FTC133 cells (Figure 5). In glucose-containing 
medium condition, WRO cells completely healed the 
wound by 48 h, whereas at this time FTC133 cells only 
covered a 50 % of the wound area. Under glucose-
deprivation condition, cell migration was much slower, 
yet this effect was particularly evident in FTC133 cells 
which essentially stopped their migration from 24 h on 
(Figure 5, Table 2). To get an insight on the functional 
link between glucose availability and cell migration, we 
monitored the uptake of glucose in migrating WRO and 
FTC133 cells in the proximity of the wound. For this 
purpose, we used 2-(N-(7-Nitrobenz-2-oxa-1,3-diazol-
4-yl)Amino)-2-Deoxyglucose (2-NBDG), a fluorescent 
analogue of glucose widely used for optical measurements 
of glucose uptake[21]. The uptake of the fluorescent probe 
was better appreciated in the cells cultured in glucose-
free medium, given that 2-NBDG competes with glucose 
for the same membrane transporter of the GLUT family. 
In this condition, the 2-NBDG fluorescent signal was 
much more intense in FTC133 cells than in WRO cells 
at any time-point, either in the vicinity of the wound 
and in the rear (Figure 6A). Thus, despite of the fact that 
cell proliferation and cell migration were much slower, 
FTC133 cells appeared more avid than WRO cells in the 
uptake of glucose. Glucose is internalized in the cells by 
glucose transporters belonging to the GLUTs family[22]. 
GLUT1 is the most prevalent isoform in highly aggressive 
and less-differentiated thyroid cancer histotypes[23-25]. 
We checked the plasmamembrane expression of GLUT1 in 
migrating WRO and FTC133 cells cultivated in glucose-
Figure 6: Differential uptake of glucose and plasmamembrane expression of GLUT1 in WRO and FTC133 cells. 
A) Glucose uptake assay in WRO and FTC133 cell lines. The uptake of the glucose fluorescent analogue 2-NBDG (in green, 50 μM) 
was monitored during glucose deprivation in proximity of the wound or far from the wound at 24 h and 48 h. Level of 2-NBDG uptake 
was higher in FTC133 cells than in WRO cells. Scale bar = 20µm. Magnification= 63X. B) Plasmamembrane expression of GLUT1 in 
proximity of the wound in WRO and FTC133 cell lines. Cells grown on coverslips were cultivated in glucose-containing or glucose-free 
culture medium for 48 h as per the wound healing assay and immunostained for GLUT1. The expression of GLUT1 in plasmamembrane 
was higher in FTC133 cells than in WRO cells. In WRO cells the membrane expression of GLUT1 increased under glucose deprivation. 
Nuclei are stained with DAPI. Scale bar = 20µm. Magnification= 63X. Data shown in this Figure have been reproduced independently 
three times. 
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containing or in glucose-free culture medium. Based on 
immunofluorescence staining, it is apparent that FTC133 
cells express GLUT1 on the plasmamembrane at level 
higher than in WRO cells (Figure 5B). It is to note that in 
WRO cells the membrane expression of GLUT1 increases 
upon incubation in glucose-free medium (Figure 6B). 
PTEN and p53 control the membrane expression 
of GLUT1 and the uptake of glucose in thyroid 
cancer cells
To definitively link PTEN and p53 to the capability 
of the cancer cells to uptake glucose, we sought to 
manipulate genetically the expression of these proteins. 
First, we employed the small interference technology to 
silence the expression of wild-type PTEN and of wild-type 
p53 in the WRO cells. After trasnfection, the cells were 
cultivated for 24 h in the presence or absence of glucose. 
As shown by immunofluorescence staining in Figure 7A, 
the transfection with the specific siRNA achieved the 
effective down-regulation of either PTEN or p53 in the 
large majority of the cells (it was estimated that >80 % of 
the cells in the monolayer were negative for the protein 
considered). It is to be noted, however, that the silencing of 
p53 was of detriment for cell survival (it was estimated that 
about 40 % of the transfected WRO cells were detached 
at the end of the incubation period). This toxic effect was 
exacerbated in the glucose-deprived culture. Next, we 
performed in a parallel set of cultures the immunostaining 
for GLUT1 and for LC3. In control un-transfected and in 
sham-transfected cells, GLUT1 clustered in a para-golgian 
area or was relocated at the plasmamembrane depending 
on whether the cells were cultivated in the presence or 
the absence of glucose (Figure 7B). To be noted, the cells 
transfected with either the siRNA specific for PTEN or 
for p53 basally showed GLUT1 on the plasmamembrane, 
regardless of the presence or absence of glucose in the 
culture medium (Figure 7B). LC3-positive autophagic 
vacuoles were clearly detected in a perinuclear region of 
the cells cultivated in the absence of glucose, consistent 
with induction of autophagy by glucose deprivation (see 
Figure 5B). Of note, LC3-positive vacuoles were also 
detected in the cells transfected with siRNA p53 cultivated 
in the presence of glucose. 
We then investigated on the functional 
consequences of the PTEN or p53 knock-down in terms 
of glucose uptake. The images shown in Figure 7C clearly 
Figure 7: Effect of PTEN and p53 gene knock-down on the cellular expression of GLUT1 and LC3 and on glucose 
uptake in WRO cells. WRO cells plated on coverslips were transfected with control duplex (sham) or with siRNA specifically targeting 
PTEN or p53. Control un-transfected cells were also included. The cells were then incubated for 24 h in glucose-containing or glucose-
free medium. At the end, the coverslips were processed for immunofluorescence staining. A) co-immunostaining of PTEN and p53; B) 
co-immunostaining of GLUT1 and LC3. C) A parallel set of cultures was used to assay the uptake of 2-NBDG. ImageJ quantification of 
cell associated 2-NBDG is included. Data are given as average of Fluorescence Intensity (FI) per cell in the selected fields. These data were 
reproduced independently two times in double. Scale bar = 20µm. Magnification= 63X.
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demonstrate that either the silencing of PTEN or of 
p53 greatly favoured the uptake of glucose. By ImageJ 
quantification it was estimated that the uptake of 2-NBDG 
in siRNA-transfected cells was on average three folds 
that in the sham-transfected counterpart and five to six 
folds that in the un-transfected control cells (Figure 7C, 
lower panel). In siRNA p53-transfected cells cultivated in 
the absence of glucose the uptake of 2-NBDG was even 
higher. Note that the stress associated to the transfection 
per se stimulated the uptake of 2-NBDG (compare sham-
transfected vs un-transfected). 
Finally, as a complementary experiment to prove 
the role of PTEN in glucose uptake, we transgenically 
expressed wild-type PTEN in the PTEN-null FTC133 
cells. After transfection with a plasmid harbouring the 
PTEN cDNA, the cells were further incubated 24 h 
in glucose-containing or glucose-free medium. A first 
set of coverslip was immunostained for PTEN and p53 
(Figure 8A). Based on immunofluorescence positivity 
it was estimated that >60 % of the transfected cells 
were efficiently expressing PTEN. Of note, the mutant 
p53 protein localized to the nucleus, especially in the 
cells cultivated in glucose-free medium (Figure 8A). 
In control un-transfected and in sham-transfected 
FTC133 cells GLUT1 was permanently localized on the 
plasmamembrane, regardless of the availability of glucose 
(Figure 8B). The ectopic expression of PTEN greatly 
compromised the membrane localization of GLUT1 
(Figure 8B). Yet, when cultivated in the absence of glucose 
GLUT1 was relocated again on the plasmamembrane 
(Figure 8A). We then looked at the consequence of 
PTEN expression on the uptake of glucose in transfected 
FTC133 cells. Strikingly, the fluorescence associated 
with the internalization of 2-NBDG was drastically 
reduced in the PTEN-transfected cultures (Figure 8C). By 
ImageJ quantification, the uptake of 2-NBDG was halved 
Figure 8: Effect of ectopic expression of PTEN in FTC133 cells on the cellular expression of GLUT1 and LC3 and on 
glucose uptake. FTC133 cells plated on coverslips were transfected with an empty pcDNA vector (sham) or with the plasmid harbouring 
the wild-type PTEN cDNA. Control un-transfected cells were also included. The cells were then incubated for 24 h in glucose-containing or 
glucose-free medium. At the end, the coverslips were processed for immunofluorescence staining. A) co-immunostaining of PTEN and p53; 
B) co-immunostaining of GLUT1 and LC3. C) A parallel set of cultures was used to assay the uptake of 2-NBDG. ImageJ quantification 
of cell associated 2-NBDG is included. Data are given as average of Fluorescence Intensity (FI) per cell in the selected fields. These data 
were reproduced independently three times. Scale bar = 20µm. Magnification= 63X.
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compared to that of control un-transfected cells, regardless 
of whether the cells were cultivated in the presence or the 
absence of glucose (Figure 8C, right panel). This effect is 
likely underestimated if one considers that the transfection 
per se stimulated the uptake of the fluorescent probe 
(compare the sham-transfected with the un-transfected 
cells) and that not all the transfected cells expressed PTEN 
at high level. 
From these data we can conclude that PTEN and 
p53 control the membrane expression of GLUT1 and the 
uptake of glucose in cancer cells. 
DISCUSSION 
In solid tumours, glucose and oxygen availability 
decrease in the most inner portion as increases the distance 
of cancer cells from the peripheral vasculature[3]. Hypoxic 
tumour cells are more aggressive and metastatic-prone, as 
they reprogram their metabolism toward aerobic glycolysis 
through HIF-1α-mediated expression of GLUT proteins 
and glycolytic enzymes[22,26]. Hypoxia has been shown 
to induce a metabolic response, mediated by the Hypoxia 
Inducible Factors (HIF) 1 and 2 alpha, that promotes the 
migration and spreading of thyroid cancer cells[27,28]. 
Interestingly, this behaviour was reinforced by the 
abnormal activation of the PI3k pathway in cells lacking 
the expression of PTEN[28]. It has also been reported that 
glycolysis is a main source of energy for malignant thyroid 
cells[29]. However, no studies have so far analyzed the 
effect of glucose depletion on the phenotypic behaviour 
of thyroid cancer cells. Here we have addressed this 
issue in the thyroid cancer cell lines WRO and FTC133, 
which differ in the expression of PTEN and p53, two 
oncosuppressor proteins that are known to play important 
roles in glucose metabolism. PTEN hyper-expression 
reduces glucose uptake and favours its mitochondrial 
oxidation, thus opposing the Warburg effect[8]. Further, 
PTEN down-regulates the PI3k-AKT-mTOR pathway, 
that transduces cell proliferation signals[30]. TP53 also 
reduces the glucose uptake and antagonizes the Warburg 
effect by controlling the expression of membrane glucose 
transporters[31] and of glycolytic enzymes[32]. Activation 
of p53 also leads to cell cycle arrest[33] and apoptosis[34]. 
Therefore, either loss of PTEN or of p53 is expected to 
increase glucose uptake and glycolysis, to promote cell 
proliferation and to impair apoptosis. Indeed, we found 
that FTC133 cells, which are PTEN deficient and express 
a mutant p53, are higher up-taker and consumer of glucose 
respect to WRO cells, which express wild-type PTEN and 
p53. Experiments of (PTEN and p53) gene silencing and 
of (PTEN) transgenic expression clearly demonstrated 
the dominant role of PTEN and p53 in driving the 
plasmamembrane localization of GLUT1 and the glucose 
uptake. Worth to note, while the wild-type p53 was 
stabilized in glucose-depleted WRO cells, the mutant p53 
was instead degraded in glucose-depleted FTC133 cells 
despite it was phosphorylated. Wild-type p53 is mainly 
degraded through the MDM2-ubiquitin-proteasome 
system[35], while the mutant p53 is degraded by either the 
chaperon-mediated autophagy[36] or the macro-autophagy 
pathway[37]. Also to be noted is that knock-down of wild-
type p53 in WRO cells was deleterious for cell survival, 
while increasing basal autophagy and glucose uptake in 
the cells. Knock-down of PTEN increased the rate of 
glucose uptake in WRO cells, and it had no side effects on 
cell viability and on the accumulation of LC3-vacuoles. 
Strikingly, the Dt of FTC133 cells was two-folds 
that of WRO cells when cultured in glucose-containing 
medium, and it further increased to four-folds when 
cultured for up to 48 h in glucose-free medium. Cell 
cycle analysis data indicated that glucose deprivation 
mainly affected the Go/G1 to S phase transition in WRO 
cells, though not toxic, while it dramatically affected the 
completion of the G2/M phase and eventually provoked 
apoptotic cell death in FTC133 cells. FTC133 expressed 
high level of plasmamembrane GLUT1, compared to 
WRO cells, which is consistent with the loss of function 
of PTEN and p53. FTC133 cells, besides being PTEN-
deficient, express the p53R273H mutant that has been 
shown to inhibit caspase-dependent apoptosis[38] 
and autophagy[39] and to promote cell migration and 
invasion[40]. Therefore, it appears counterintuitive 
that prolonged glucose depletion could lead FTC133 to 
caspase-dependent cell death. Not only, FTC133 cells also 
showed a reduced migration rate compared to WRO cells, 
and this difference was more evident in glucose-depleted 
conditions. Autophagy was not inhibited in FTC133, yet 
chronic glucose-depletion led to impaired consumption 
of the autophagosomes, likely as a consequence of 
insufficient energy. Taken together, these facts indicate 
that FTC133 cells rapidly consume glucose, thus soon 
becoming glucose-addicted. In this respect, it is to be 
stressed that FTC133 cells were cultivated in a medium 
containing much more glucose than that used for culturing 
WRO cells (4.5 g/L vs 2 g/L). 
We hypothesize that the synergistic effects of 
combined PTEN loss-of-function and mutant p53 gain-of-
function lead to a metabolic dependence on glucose with 
unpredicted impact on cell behaviour, that differs from that 
described for individual oncosuppressor gene alteration. 
Of particular relevance is the impairment of the autophagy 
flux in glucose-depleted cells, which may account for loss 
of protection against the metabolic stress. 
It is now clear that the malignant behaviour of 
cancer cells results from the combination of mutations 
with gain-of-function or loss-of-function that involve at 
least five to seven oncogenes and oncosuppressor genes. 
In addition, epigenetic events contribute to the altered 
expression of key regulatory proteins. The presence of 
pro-oxidant molecules and of inflammatory cytokines 
in the tumour micro-environment further contributes 
to modify the gene expression in cancer cells. Thus, 
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cancers that develop spontaneously soon become a very 
heterogeneous population of subclones each with its 
unique set of alterations in the expression of oncogenes 
and oncosuppressors, as well as of key metabolic 
regulators. This explains why a drug targeting one single 
pathway, while effective in experimental models (in which 
only one gene is the dominant driver), often fails when 
translated into the clinic for the therapy of spontaneous 
tumours. 
Whatever the set of genes altered, for their 
proliferation and migration the cancer cells need energy 
and this depends on the availability of oxygen and 
nutrients such as glucose and aminoacids (among which 
glutamine is the most important). Thus, targeting the 
energetic metabolism of cancer cells may be the clue 
to revolutionize cancer treatment[41-43]. In particular, 
glucose availability and glycolysis have been shown 
causally linked to chemoresistance, proliferation and 
metastasization of tumours[44-46]. Therefore, glucose-
restriction is expected to elicit beneficial effect against 
glucose-addicted cancer cells. Indeed, there are indications 
in this sense. Reducing the uptake of glucose with the 
GLUT1 inhibitor Phloretin favoured doxorubicin toxicity 
in P-glycoprotein expressing chemoresistant cancer 
cells[47]. In addition, the administration of 2-deoxy-
D-glucose, a glucose analogue that impairs glycolysis, 
enhanced the clinical efficacy of radio- and chemotherapy 
in glioblastomas[48] and in anaplastic thyroid cancer[49]. 
Consistent with the role of glucose availability in cancer 
progression, it was found that a higher dietary glucose 
intake significantly associated with an increased risk 
of recurrence and mortality in stage III colon cancer 
patients[50]. 
Here we have shown that the concurrent deletion 
of PTEN and mutation of p53 exacerbates glucose uptake 
and consumption in FTC133 cancer cells, which undergo 
cell cycle arrest and apoptosis, cell migration arrest and 
manifest defective autophagy when subjected to glucose-
restriction. Therefore, targeting together the PI3k-(PTEN)-
AKT-mTOR and the p53 pathways, that control both 
glucose uptake and autophagy, could be an efficacious 
strategy to cure aggressive cancers. 
MATERIALS AND METHODS
Cells and treatments 
The WRO and FTC133 follicular thyroid cancer 
cell lines were kindly provided by Dr. Francesco Frasca, 
University of Catania, Italy. WRO cells were cultured 
in RPMI 1640 (with L-glutamine) completed by foetal 
bovine serum (FBS, 10%) and penicillin/streptomycin 
(1%); the FTC133 cells were cultured in Dulbecco’s 
Modified Eagle Medium, Nutrient mixture F-12 (1:1, by 
volume) completed by FBS (10%), penicillin/streptomycin 
(1%) and L-glutamine (1%). All culture reagents were 
purchased from Sigma-Aldrich (Germany). For studies on 
glucose deprivation, the cells were incubated in complete 
culture medium or medium without glucose (R1383 and 
D5030, Sigma-Aldrich) for up to 48h. For the experiments, 
growing cells were plated on sterile plastic dishes or on 
sterile glass coverslips and allowed to adhere for at least 
24 h before the use. The PI3K inhibitor 3-methyladenine 
(3MA; Sigma-Aldrich) was used at 10 mM. Ammonium 
Chloride (NH4Cl) was used at 10 mM. At the end of the 
incubations, the cells or coverslips were collected and 
processed as detailed below.
Cell proliferation, cell cycle and cell death assay
Cell growth was assessed by manual and 
hemocytometer cell counting of adherent viable (trypan 
blue-excluding) cells. Doubling Time (Dt) was calculated 
using the free software Doubling Time Online Calculator 
(http://www.doubling-time.com/compute.php). Cell 
death was assessed by counting the trypan blue-stained 
cells (necrotic cells) and by cytofluorometric analysis 
of Annexin V-Propidium Iodide double stained cells, as 
previously reported[51,52]. For this purpose, floating 
(dead) cells and attached cells were combined. Cell cycle 
analysis was performed by cytofluorometry of Propidium 
Iodide labelled cells using the software WinMDI 2.9. 
Wound-healing migration assay
The cells were plated on Petri dishes and cultured 
for at least 48 h till confluence. A wound was made by 
dragging a sterile blue pipette tip along the centre of 
the plate[53]. Detached cells were washed out twice, 
and cultures were then incubated for up to 48 h with no 
changes of medium in Glucose-containing or Glucose-
free medium. Images of cell monolayers were taken at the 
time indicated under the phase-contrast microscope with 
a digital camera. The wound wideness was calculated 
by measuring the mean distance between the margins 
of the wound in randomly selected fields, directly on 
photographs. Migration was quantified by calculating the 
area of wound at time points t0(time of wound), t24 (24 h 
after wound) and t48 (48 h after wound). Normalization 
was obtained by the formula [area(t0) − area(t24 or 48)]/
area(t0). Overall, four independent experiments were 
performed. 
In other experiments, the cell were cultured up 
to confluence on sterile glass coverslips and wounded 
as described above, except that a yellow pipette tip 
was used. At the end of the incubations, the cells on 
coverslips were fixed, permeabilized and processed for 
immunofluorescence staining. Alternatively, the living 
cells were assayed for glucose uptake. 
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Glucose uptake assay and measurement
The fluorescent glucose analogue 2-[N-(7-nitrobenz-
2-oxa-1,3-diazol-4-yl)amino]-2-deoxy-d-glucose (2-
NBDG; Life Technologies Co, Carlsbad, CA, USA) 
was used to detect glucose uptake in living cells[20]. 
Cells grown on coverslips were incubated with 50 µM 
of 2-NBDG for 1 h before the end of the treatments, 
washed twice with PBS 1x and rapidly imaged under 
the fluorescence microscope. Image processing and 
data quantification of the area and of the intensity of 
fluorescence images were performed with the software 
ImageJ 1.48v (http://imagej.nih.gov/ij/). At least five 
randomly chosen fields for a total of minimum 50 cells 
were analysed. Fluorescence Intensity (FI) is given in 
arbitrary units as an average value per cell in the selected 
representative fields. 
Immunofluorescence staining 
The cells adherent on sterile glass coverslips were 
fixed in cold methanol for 20 min and permeabilized 
with 0.2% Triton X-100 in PBS1X for 10 min. Overnight 
incubation in cold room was performed with the following 
primary antibodies: rabbit polyclonal anti-GLUT1 
(Millipore, Darmstadt, Germany; dilution 1:50); rabbit 
polyclonal anti-PTEN (Millipore; dilution 1: 200); mouse 
monoclonal anti-p53 (Santa Cruz Biotechnology, Santa 
Cruz, CA; dilution 1:100) and mouse monoclonal anti-
LC3 (nanoTools, Teningen, Germany; dilution 1:100). 
As secondary antibody (dilution 1:600) the IRIS-2 
(green fluorescence)-con jugated goat-anti-rabbit IgG 
secondary or IRIS-3 (red fluorescence)-conjugated goat-
anti-mouse IgG (Cyanine Technologies SpA, Turin, Italy) 
was used as appropriate for 1 h at room temperature in 
a humid chamber. Nuclear chromatin was stained with 
the fluorescent dye 4,6-diamidino- 2-phenylindole-
dihydrochloride (DAPI). As negative control, the 
primary antibody was omitted or substituted with pre-
immune antiserum. Antibodies were diluted in PBS 
containing 0.1% Triton X-100 and 10% FBS. Stained 
cells were mounted with Slow-FADE (Light AntiFADE 
Kit, Molecular Probes Invitrogen, Carlsbad, CA, USA) 
and observed under a fluorescence microscope (Leica 
DMI6000B, Leica Microsystem AG, Wetzlad, Germany). 
Western blotting assay
Immunoblotting was performed following standard 
procedures as previously reported.54 Cell homogenates 
were prepared by freeze–thawing and ultrasonication in 
a buffer containing detergents and protease inhibitors. 30 
μg of cell proteins were denatured with Laemmli sample 
buffer, separated by electrophoresis on a 12.5% SDS-
containing polyacrylamide gel and then electroblotted 
onto PVDF membrane (Carlo Erba reagents, Milan, Italy). 
The filter was first probed with the antibody specific for 
the protein of interest. The following primary antibodies 
were used: Rabbit polyclonal anti-PTEN (EX-BIO, Vestec, 
Czech Republic); rabbit polyclonal anti-LC3 (Sigma-
Aldrich); rabbit polyclonal anti-phospho p53 (Ser15) (Cell 
Signaling technology, Danvers, Massachusetts, USA) and 
mouse monoclonal anti-p53 (Santa Cruz Biotechnology). 
The filter was subsequently stripped and re-probed with 
an antibody specific for β-tubulin (Sigma-Aldrich), as 
an index of homogenate protein loading in the lanes. 
Immunocomplexes were revealed by using a peroxidase-
conjugated secondary antibody (Bio-Rad, California, 
USA), as appropriate, and subsequent peroxidase-induced 
chemiluminescence reaction (PerkinElmer, Massachusetts, 
USA). Densitometry of Western Blot bands was performed 
with the Quantity One-4.5.0 software (Bio-Rad) and with 
the free software Image J (1.48v; http://imagej.nih.gov/ij/).
Small interference RNA and plasmid transfections 
The reagents and the methods have been previously 
described[55]. Post-transcriptional gene silencing 
was obtained using a specific small interference RNA 
(siRNA) directed against the mRNA of PTEN (the sense 
strand was 5′–AGACUUGAAGGCGUAUACA-3′) 
or of p53 (the sense strand was 
5’-AAGAAACCACUGGAUGGAGAAUAUUUC-3’). A 
control duplex was used for sham-transfection. Duplexes 
of nucleotide siRNA were purchase from MWG Biotech 
AG (Ebersberg, Germany). In brief, the cells were 
plated and let adhere on coverslips for at least 24 h, then 
incubated for 6 h with 30 pmol RNA-duplexes in the 
presence of 7.5 μl Lipofectamine 3000 (Invitrogen Co) 
diluited in 250 µl of Optimem (Life Technologies Co). The 
cells were then washed and further incubated 36 h post-
transfection to allow maximal effect on protein down-
regulation before use.
Transgenic expression of wild type PTEN was 
obtained by Lipofectamine 3000 (Invitrogen Co) 
transfection with a pcDNA3.1Zeo+ plasmid containing 
the specific full-length cDNA. An empty pcDNA3.1Zeo+ 
plasmid was used for sham transfection. In brief, the 
cells adherent on coverslips were incubated for 6 h with 
5 µg/μl of DNA in the presence of 7.5 μl Lipofectamine 
3000 (Invitrogen Co) diluited in 250 µl of Optimem (Life 
Technologies Co). Then washed and incubated 36 h post-
transfection.
Statistics
Unless otherwise specified, all experiments were 
replicated independently three times and in double or 
triplicate. Data are given as average ± S.D. Statistical 
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significance was taken for p values <0.05. 
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